tirzepatide nausea treatment Mounjaro Side Effects | Dealing With Side Effects Tirzepatide Dosing - A Patient
Description
According to Pharmarack data, GLP-1 sales in India were already growing 178 percent year-on-year in February 2026, taking moving annual turnover to Rs.14.46 billion
The present study (Nicholls et al, 2025) SURPASS-CVOT (Study of Tirzepatide Compared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes) was a double-blind, randomised, active-comparator study to determine non-inferiority of tirzepatide 15 mg (or highest tolerated dose) versus dulaglutide 1.5 mg in terms of 3-point MACE, in people aged 50 years with type 2 diabetes and established CVD
Navigating healthcare can be challenging, but finding the right primary care physician shouldn't be
Dispose of the syringe safely in a sharps container
